Get 40% Off
💎 WSM is up +52.1% since our AI picked it in December! Unlock all premium stock picksUnlock now

7 biggest deal reports this week: Horizon Therapeutics surges on takeover talks

Published 04/12/2022, 10:14 am
Updated 04/12/2022, 10:14 am
© Reuters.

© Reuters.

Here are 7 head-turning deal dispatches from the past week, as covered first on InvestingPro+.

1. Arco Platform (NASDAQ:ARCE) announced it had received a non-binding going private proposal from General Atlantic and Dragoneer Investment Group for $11 per share, which represent an approximately 22% premium over the prior most recent closing price of $9.04.

The proposal states that the founders (Oto Brasil de Sá Cavalcante and Ari de Sá Cavalcante Neto) support the offer and will roll over 100% of their Class A common shares and Class B common shares in the transaction, and that after the closing, the founders will maintain the same economic and voting interest in the company as they currently have. The company cautions its shareholders and others considering trading in its securities that no decisions have been made with respect to the company's response to the proposal. Shares gained 43% to $12..41 for the week.

2. Hewlett Packard Enterprise (NYSE:HPE) has expressed takeover interest in Nutanix (NASDAQ:NTNX), according to a report from Bloomberg, citing people familiar with the matter. Nutanix shares gained 6.8% to $30.53. HPE shares rose 6.3% to $16.69.

3. Aerojet Rocketdyne (NYSE:AJRD) is seeing multiple bidders, according to Reuters, which says General Electric (NYSE:GE) L3Harris Technologies (NYSE:LHX), Textron (NYSE:TXT), and Veritas Capital are all vying to acquire the company. Aerojet shares gained 7.4% to $54.57 for the week.

4. EQT (NYSE:EQT) is in talks to acquire Radius Global Infrastructure Inc (NASDAQ:RADI) according to a report from Bloomberg, citing people with knowledge of the matter. EQT is speaking to banks about financing. No deal has been reached and talks could still collapse, the report cautioned. Radius shares gained 16.5% for the week to $12.88. EQT lost 3.7% to $39.93.

5. Shares of Horizon Therapeutics (NASDAQ:HZNP) surged after the company confirmed that it was in "highly preliminary" takeover talks with Amgen Inc (NASDAQ:AMGN), Janssen Global Services, LLC and Sanofi (EPA:SASY) (NASDAQ:SNY). The confirmation followed shortly after a Wall Street Journal article reported that the biopharma company was fielding takeover interest from large pharmaceutical companies. The Journal story added that with a typical takeover premium it could fetch a price well over $20 billion in a deal.

Horizon said the talks with the three parties "may or may not lead to an offer being made for the entire share capital of the Company." The company was forced to make the disclosure in accordance with Rule 2.6 of the Irish Takeover Rules, where it is based. Shares gained 34% for the week to $104.85.

6. Boston Scientific Corporation (NYSE:BSX) agreed to acquire Apollo Endosurgery (NASDAQ:APEN), Inc. for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million. Shares gained 5.9% to $46.60 for the week.

7. Amwell (NYSE:AMWL) is in talks to buy Talkspace Inc (NASDAQ:TALK) at $1.50 per share, per Calcalist. Talkspace shares gained 14% to $0.85 for the week. Amwell gained 6.4%.

***

If you’re interested in upgrading your search for new investing ideas, check out InvestingPro+

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.